Fairvalue-Calculator Fairvalue-Calculator
EN DE

Brii Biosciences Limited (BRIBF) Fair Value & Analysis

Healthcare · US · Market cap $108M

Price$0.1495
Fair Value$0.1559
Upside+4.3%
Quality92/100
Evidence: Low Range $0.1028 – $0.1947

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Brii Biosciences Limited (BRIBF) currently trades at $0.1495, while our model-based Fair Value estimate is $0.1559 — implying the stock looks roughly 4.3% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Brii Biosciences Limited (BRIBF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.1559 versus a price of $0.1495 — about +4% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BRIBF?
Our 21-model fair value for Brii Biosciences Limited is $0.1559 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1495.
What is the quality score of BRIBF?
Brii Biosciences Limited has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.